Ridgeline Therapeutics
Pre-clinicalWe are a Houston-based biotech company developing safe and effective drugs that selectively target new mechanisms-of-action to reverse age-related muscle weakness (sarcopenia/frailty), Type 2 diabetes,
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $95M
About
We are a Houston-based biotech company developing safe and effective drugs that selectively target new mechanisms-of-action to reverse age-related muscle weakness (sarcopenia/frailty), Type 2 diabetes,
Small Molecules
Funding History
2Total raised:$95M
Series A$80MJan 15, 2023
Seed$15MSep 15, 2021